https://doi.org/10.46344/JBINO.2025.v14i03.28

THE NITROGEN CASCADE IN SICKLE CELL PATHOPHYSIOLOGY: TARGETS FOR THERAPY

***Emmanuel Ifeanyi Obeagu**

Department of Biomedical and Laboratory Science, Africa University, Zimbabwe, E-mail: emmanuelobeagu@yahoo.com, obeague@africau.edu, ORCID: 0000-0002-4538-0161

ABSTRACT

The nitrogen cascade, comprising interconnected metabolic pathways involving nitric oxide (NO), L-arginine, and related nitrogenous intermediates, plays a pivotal role in vascular regulation, immune modulation, and oxidative balance. In sickle cell disease (SCD), this cascade becomes profoundly dysregulated due to chronic hemolysis, oxidative stress, and systemic inflammation. The release of free hemoglobin and arginase from lysed erythrocytes scavenges NO and depletes L-arginine, respectively, resulting in endothelial dysfunction and impaired vasodilation. These disruptions not only contribute to vaso-occlusive events but also underlie the development of chronic complications such as pulmonary hypertension, leg ulcers, and renal impairment. Mechanistically, the altered nitrogen cascade in SCD is characterized by increased levels of asymmetric dimethylarginine (ADMA), enhanced reactive nitrogen species like peroxynitrite, and uncoupling of endothelial nitric oxide synthase (eNOS), all of which exacerbate oxidative and nitrosative stress. This pathophysiological shift perpetuates vascular inflammation, promotes leukocyte adhesion, and disrupts immune homeostasis. Understanding these biochemical perturbations provides a unified framework for investigating disease progression and identifying molecular targets for therapeutic intervention.

Keywords: *Nitrogen metabolism, Sickle cell disease, Nitric oxide, Vascular dysfunction, Therapeutic targets*

Introduction

Sickle cell disease (SCD) is a complex genetic disorder characterized by the abnormal polymerization of deoxygenated hemoglobin S (HbS), leading to sickling of erythrocytes and their subsequent destruction. This hemolytic process triggers a cascade of pathological events, including endothelial dysfunction, chronic inflammation, and vascular complications, which significantly contribute to the morbidity and mortality of SCD patients. While the central focus has traditionally been on the structural defects in hemoglobin, recent studies have highlighted the important role of metabolic pathways, particularly the nitrogen cascade, in the pathophysiology of the disease. Nitric oxide (NO), a key molecule in this cascade, is crucial for maintaining vascular homeostasis and immune function, yet its availability is severely compromised in SCD due to multiple disease-related factors [1-3]. The nitrogen cascade refers to a series of interconnected biochemical processes involving nitrogen-containing molecules such as NO, arginine, citrulline, and other nitrogenous intermediates. In normal physiology, NO is synthesized from L-arginine by endothelial nitric oxide synthase (eNOS), and this process plays a critical role in regulating vascular tone, inhibiting platelet aggregation, and controlling vascular inflammation. However, in SCD, a variety of factors, including chronic hemolysis, oxidative stress, and inflammation, interfere with this pathway. The release of free hemoglobin from lysed red blood cells scavenges NO, and excess arginase activity, released from inflammatory cells, further depletes the L-arginine substrate required for NO synthesis. These disturbances in the nitrogen cascade contribute to endothelial dysfunction, impaired vasodilation, and increased vascular resistance, which exacerbate the clinical manifestations of SCD [4-6].

One of the key pathophysiological features of SCD is vaso-occlusion, which leads to acute pain crises, organ ischemia, and tissue damage. NO deficiency plays a central role in this process, as NO is essential for the maintenance of endothelial function and the prevention of platelet aggregation and leukocyte adhesion. In the absence of adequate NO production, vasoconstriction, microvascular occlusion, and thrombus formation become more pronounced, contributing to the ischemic events that define sickle cell crises. Furthermore, a lack of NO bioavailability is implicated in the chronic complications of SCD, such as pulmonary hypertension, renal dysfunction, and leg ulcers, all of which are associated with poor prognosis and reduced quality of life [7-9]. In addition to NO, the nitrogen cascade in SCD is also influenced by the activity of arginase, an enzyme that hydrolyzes L-arginine to ornithine and urea. Elevated arginase activity in SCD, particularly due to hemolysis, shifts the metabolism of L-arginine away from NO production and toward the synthesis of polyamines and proline, which are involved in collagen synthesis and vascular remodeling. This imbalance contributes to vascular fibrosis, smooth muscle cell proliferation, and endothelial dysfunction, further exacerbating the disease's vascular complications. Additionally, dysregulated polyamine and urea cycle metabolism in SCD can result in altered immune responses, inflammatory cascades, and oxidative stress, all of which contribute to disease progression [10-12].

Aim

The aim of this review is to explore the role of the nitrogen cascade in the pathophysiology of sickle cell disease (SCD) and to evaluate the therapeutic potential of targeting nitrogen metabolism pathways for the management of clinical manifestations associated with the disease.

The Nitrogen Cascade: Biochemical Framework and Disruption in SCD

The nitrogen cascade is a sequence of interconnected biochemical processes that involve nitrogen-containing molecules, primarily nitric oxide (NO), L-arginine, and other nitrogenous intermediates. At the core of this cascade is the synthesis of NO from L-arginine, a reaction catalyzed by endothelial nitric oxide synthase (eNOS) in endothelial cells. NO plays a critical role in maintaining vascular tone, inhibiting platelet aggregation, reducing leukocyte adhesion, and modulating smooth muscle cell function. In a healthy individual, the production of NO ensures normal endothelial function and vascular health, promoting vasodilation, improving blood flow, and preventing thrombus formation [13-14]. In normal conditions, L-arginine serves as the substrate for NO production via eNOS, but it also feeds into other metabolic pathways. For example, L-arginine can be metabolized by arginase into ornithine and urea, both of which play roles in tissue repair, collagen synthesis, and immune function. Under physiological conditions, this metabolic balance between NO production and arginase activity is tightly regulated. However, in sickle cell disease (SCD), this equilibrium is significantly disrupted, contributing to the pathophysiology of the disease [15]. The disruption of the nitrogen cascade in SCD is primarily driven by hemolysis and the associated release of free hemoglobin into the bloodstream. Free hemoglobin binds and scavenges NO, reducing the bioavailability of this critical molecule. This is a key factor in the endothelial dysfunction observed in SCD, as decreased NO levels impair vasodilation and contribute to increased vascular resistance. In addition, the oxidative stress generated by free hemoglobin accelerates the conversion of NO into toxic reactive nitrogen species (RNS), such as peroxynitrite. These RNS further damage endothelial cells, exacerbate vascular inflammation, and promote tissue injury, creating a vicious cycle that worsens disease outcomes [16].

Another major factor that disrupts the nitrogen cascade in SCD is the elevated activity of arginase. Arginase is released from erythrocytes during hemolysis, as well as from activated neutrophils and macrophages in response to inflammation. The increased arginase activity in SCD shifts the metabolism of L-arginine away from NO production, instead favoring the generation of ornithine and polyamines. These byproducts contribute to vascular remodeling and fibrosis, which can lead to smooth muscle cell proliferation and endothelial dysfunction. Elevated arginase activity also reduces the availability of L-arginine for eNOS, further compounding the NO deficiency and worsening the disease's vascular complications [17-18]. Furthermore, the accumulation of asymmetrical dimethylarginine (ADMA), an endogenous inhibitor of eNOS, in SCD also exacerbates the disruption of the nitrogen cascade. ADMA competes with L-arginine for binding to eNOS, limiting the enzyme's ability to produce NO. Elevated ADMA levels in SCD are thought to result from increased oxidative stress and hemolysis, further impairing NO production and contributing to endothelial dysfunction. The combined effects of reduced NO bioavailability, increased arginase activity,

and the accumulation of ADMA set the stage for the vascular and immune dysregulation seen in SCD [19-20].

Clinical Manifestations Linked to Nitrogen Dysregulation in Sickle Cell Disease (SCD)

The dysregulation of the nitrogen cascade in sickle cell disease (SCD) plays a central role in the development of many clinical manifestations and complications associated with the disorder. As outlined earlier, the imbalance in nitric oxide (NO) bioavailability, increased arginase activity, and the accumulation of harmful nitrogen species such as asymmetrical dimethylarginine (ADMA) contribute to widespread endothelial dysfunction, impaired vasodilation, and vascular inflammation. These biochemical alterations underlie several of the hallmark clinical features of SCD, including vaso-occlusive crises, chronic pain, pulmonary hypertension, renal dysfunction, and leg ulcers [21-22]. One of the most prominent clinical manifestations of SCD is vaso-occlusion, which is the hallmark of acute pain crises. The reduced NO bioavailability due to hemoglobin scavenging and arginase-mediated depletion of L-arginine leads to impaired vasodilation and increased microvascular tone. This results in the occlusion of small blood vessels, causing ischemia, pain, and tissue damage. Furthermore, in the context of sickle cell disease, this impaired vasodilation is compounded by a hypercoagulable state and an increase in platelet aggregation, both of which contribute to thrombotic events in small vessels. These vaso-occlusive episodes can affect multiple organs, including the brain, lungs, kidneys, and spleen, leading to severe complications such as stroke, acute chest syndrome, organ infarction, and splenic sequestration [23-24].

In addition to acute vaso-occlusive events, chronic pulmonary hypertension (PH) is a major complication in individuals with SCD. Pulmonary hypertension, which is characterized by elevated pressure in the pulmonary arteries, is directly linked to disrupted nitrogen signaling. The lack of NO availability in the pulmonary vasculature results in impaired vasodilation and endothelial dysfunction, which contributes to the narrowing of pulmonary vessels and increased vascular resistance. This leads to right ventricular hypertrophy, progressive heart failure, and reduced oxygen delivery to peripheral tissues. Clinical manifestations of pulmonary hypertension in SCD patients include dyspnea, fatigue, and chest pain, and the condition is associated with a high mortality rate in severe cases [25-26]. Renal complications are also common in individuals with SCD, and chronic kidney disease (CKD) is often exacerbated by NO dysregulation. The kidneys, particularly the glomeruli, rely heavily on proper nitric oxide signaling to maintain renal blood flow, glomerular filtration, and sodium homeostasis. In SCD, the reduced NO bioavailability and oxidative stress can cause glomerular endothelial dysfunction, contributing to kidney damage and the development of proteinuria, glomerulosclerosis, and, eventually, end-stage renal disease. Additionally, hemolysis-induced release of free hemoglobin can lead to kidney injury by promoting oxidative damage and inflammation. This renal involvement can lead to fluid retention, hypertension, and electrolyte imbalances, further complicating the management of SCD [27-28].

Another clinical manifestation linked to nitrogen dysregulation in SCD is the development of leg ulcers. These chronic, non-healing ulcers often occur in the lower extremities and are common in individuals with long-standing SCD. The poor blood

flow and hypoxia associated with vaso-occlusion, combined with impaired NO-mediated vasodilation, create an environment conducive to the formation of these ulcers. Furthermore, the lack of NO contributes to chronic endothelial dysfunction and reduced tissue perfusion, delaying wound healing and making the ulcers prone to infection. Patients with leg ulcers often experience pain, significant disability, and reduced quality of life [29-30]. Stroke is one of the most devastating complications of SCD, particularly in children. Nitrogen dysregulation contributes to the increased risk of stroke by promoting endothelial dysfunction, which disrupts cerebral blood flow. Reduced NO production leads to vascular stiffness and impaired autoregulation of cerebral blood vessels, increasing the likelihood of cerebrovascular accidents. The elevated blood viscosity associated with sickle cell anemia, combined with the reduced microvascular perfusion, contributes to the formation of blood clots in the brain, leading to ischemic strokes. The impact of stroke in SCD patients is profound, with long-term neurological deficits and significant morbidity [31-32].

Therapeutic Targets and Interventions

Given the significant role of nitrogen dysregulation in sickle cell disease (SCD) pathophysiology, numerous therapeutic strategies have been explored to restore the balance of the nitrogen cascade and improve disease outcomes. These interventions primarily focus on increasing nitric oxide (NO) bioavailability, inhibiting arginase activity, and reducing oxidative stress, all of which can potentially mitigate the vascular and immune dysfunctions associated with SCD. Several pharmacological agents and biologic therapies targeting these processes are currently being studied or used in clinical settings to alleviate symptoms and prevent complications in SCD patients [33]. One of the most studied therapeutic strategies involves the administration of L-arginine, the precursor required for NO synthesis. L-arginine supplementation aims to restore the depleted pool of L-arginine, thereby enhancing NO production by endothelial nitric oxide synthase (eNOS). Studies have shown that L-arginine supplementation can improve endothelial function, enhance vasodilation, and reduce the frequency of vaso-occlusive crises in SCD patients. Additionally, L-arginine has been demonstrated to have potential benefits in reducing pulmonary hypertension and improving exercise capacity in SCD patients. Despite these promising findings, the clinical effectiveness of L-arginine supplementation has shown mixed results, with some studies indicating modest benefits and others revealing limited impact on disease severity. Further research is necessary to determine the optimal dosage, treatment duration, and patient subgroups most likely to benefit from L-arginine therapy [34].

NO donors represent another promising therapeutic intervention aimed at restoring NO bioavailability in SCD. NO donors such as sodium nitrite, nitroglycerin, and inhaled NO are designed to directly supply NO to the circulation, bypassing the impaired eNOS pathway. These agents can induce vasodilation, reduce platelet aggregation, and improve overall blood flow, all of which are beneficial in the context of SCD. Inhaled NO, for instance, has been shown to improve oxygenation and reduce the severity of acute chest syndrome, a common complication in SCD. Although NO donor therapies show potential in managing acute episodes, their long-term use is limited by concerns regarding tolerance, side effects, and the complex regulation of NO homeostasis. As such, their clinical application in SCD remains

under investigation, and more studies are required to assess their safety and efficacy over extended periods [35]. Arginase inhibitors have emerged as a novel approach to counteract the increased activity of arginase, an enzyme that competes with eNOS for the substrate L-arginine. By inhibiting arginase, these therapies can redirect the metabolism of L-arginine back toward NO production, thus restoring vascular function. Preclinical studies have demonstrated that arginase inhibitors, such as Nω-hydroxy-nor-arginine (Nor-NOHA), can improve endothelial function, reduce vascular inflammation, and ameliorate the severity of vaso-occlusion in SCD animal models. In clinical settings, arginase inhibition may offer benefits in reducing the chronic vascular dysfunction seen in SCD and could potentially prevent organ damage in the long term. However, further clinical trials are needed to confirm the safety and therapeutic efficacy of these inhibitors in human SCD patients [36].

Another therapeutic approach focuses on the reduction of oxidative stress in SCD. The imbalance between NO and reactive oxygen species (ROS) exacerbates endothelial dysfunction and promotes the conversion of NO into peroxynitrite, a potent oxidative agent that damages vascular tissues. Antioxidant therapies, including the use of agents such as hydroxyurea, ascorbic acid (vitamin C), and N-acetylcysteine (NAC), aim to neutralize ROS and restore the balance between oxidative stress and antioxidant defenses. Hydroxyurea, a well-established therapy for SCD, has been shown to increase fetal hemoglobin (HbF) levels and reduce hemolysis, thereby improving NO bioavailability indirectly. Studies also suggest that antioxidants may improve vascular health and reduce the incidence of vaso-occlusive crises, although the overall clinical benefit remains variable across patient populations [37]. Gene therapy represents a more advanced therapeutic strategy for addressing the root causes of SCD, including nitrogen dysregulation. By introducing genetic modifications that promote the production of normal hemoglobin or enhance the synthesis of NO, gene therapy has the potential to offer a permanent solution to the underlying metabolic disturbances. For instance, gene editing techniques such as CRISPR-Cas9 could potentially correct the sickle cell mutation or modify genes involved in NO metabolism to restore normal function. Although gene therapy holds immense promise, it is still in the early stages of clinical development, and the safety, efficacy, and cost-effectiveness of these approaches need to be thoroughly evaluated before they can be widely implemented [37].

Conclusion

The nitrogen cascade plays a pivotal role in the pathophysiology of sickle cell disease (SCD), influencing key aspects of vascular health, inflammation, and tissue damage. Dysregulation within this cascade, particularly the impaired nitric oxide (NO) bioavailability, contributes significantly to the hallmark clinical manifestations of SCD, including vaso-occlusion, pulmonary hypertension, stroke, renal dysfunction, and leg ulcers. These manifestations underscore the importance of maintaining a delicate balance in nitrogen metabolism for preserving endothelial function, vascular homeostasis, and overall disease management. Disruptions in this cascade, stemming from hemoglobin-NO interactions, arginase activity, and oxidative stress, are central to the disease's severity and progression. Therapeutic interventions targeting the nitrogen cascade hold great promise for

alleviating the complications associated with SCD. Approaches such as L-arginine supplementation, NO donors, arginase inhibitors, and antioxidants aim to restore NO bioavailability, reduce oxidative damage, and promote vascular function. Additionally, gene therapy represents a potentially transformative approach to addressing the genetic basis of SCD, offering a future direction for long-term disease modification. While many of these treatments show promise in preclinical and early clinical settings, the challenge remains in optimizing their efficacy, safety, and accessibility for diverse patient populations.

References

1. Gupta A. Sickle Cell Anemia and Related Hemoglobinopathies. InDecision Making Through Problem Based Learning in Hematology: A Step-by-Step Approach in patients with Anemia 2024: 269-289. Singapore: Springer Nature Singapore.
2. Hassan MS, Nasrin T, Mahalka A, Hoque M, Ali S. A perspective on the genesis, diagnostics, and management of sickle cell disease. Egyptian Journal of Medical Human Genetics. 2024; 25(1):150.
3. Rajput HS, Kumari M, Talele C, Sajan C, Saggu V, Hadia R. Comprehensive Overview Of Sickle Cell Disease: Global Impact, Management Strategies, And Future Directions. Journal of Advanced Zoology. 2024; 45(1).
4. Obeagu EI. Role of Autophagy in Modulating Oxidative Stress in Sickle Cell Disease: A Narrative Review. Int. J. Curr. Res. Chem. Pharm. Sci. 2024;11(8):38-46.
5. Obeagu EI. Redox Regulation of Hemoglobin in Sickle Cell Disease: A Review. Int. J. Curr. Res. Chem. Pharm. Sci. 2024;11(8):13-9.
6. Obeagu EI, Bunu UO, Obeagu GU, Habimana JB. Antioxidants in the management of sickle cell anaemia: an area to be exploited for the wellbeing of the patients. Int Res Med Health Sci. 2023 Sep 11;6:12-7.
7. Xiao R, Li L, Zhang Y, Fang L, Li R, Song D, Liang T, Su X. Reducing carbon and nitrogen loss by shortening the composting duration based on seed germination index (SCD@ GI): feasibilities and challenges. Science of The Total Environment. 2024:172883.
8. Lin W, Lv X, Wang Q, Li L, Zou G. Nitrogen concentration dependent optical defects transition in single crystal diamond through low pressure high temperature annealing. Vacuum. 2025:114329.
9. Wood KC, Granger DN. Sickle cell disease: role of reactive oxygen and nitrogen metabolites. Clinical & Experimental Pharmacology & Physiology. 2007 Sep 1;34(9).
10. Dijkmans T, Djokic MR, Van Geem KM, Marin GB. Comprehensive compositional analysis of sulfur and nitrogen containing compounds in shale oil using GC× GC–FID/SCD/NCD/TOF-MS. Fuel. 2015; 140:398-406.
11. Muehle M, Asmussen J, Becker MF, Schuelke T. Extending microwave plasma assisted CVD SCD growth to pressures of 400 Torr. Diamond and Related Materials. 2017; 79:150-163.
12. Obeagu EI, Obeagu GU. Immunization strategies for individuals with sickle cell anemia: A narrative review. Medicine. 2024; 103(38):e39756.
13. Obeagu EI. Strategies for reducing child mortality due to sickle cell disease in Uganda: a narrative review. Annals of Medicine and Surgery.:10-97.
14. Obeagu EI. Erythropoeitin in sickle cell anaemia: a review. International Journal of Research Studies in Medical and Health Sciences. 2020;5(2):22-8.
15. Obeagu EI, Obeagu GU. Malnutrition in sickle cell anemia: prevalence, impact, and interventions: a review. Medicine. 2024 May 17;103(20):e38164.

16. Quemada M, Delgado A, Mateos L, Villalobos FJ. Nitrogen fertilization I: The nitrogen balance. InPrinciples of agronomy for sustainable agriculture 2024: 377-401. Cham: Springer International Publishing.
17. Krug EC, Winstanley D. The need for comprehensive and consistent treatment of the nitrogen cycle in nitrogen cycling and mass balance studies: I. Terrestrial nitrogen cycle. Science of the total environment. 2002; 293(1-3):1-29.
18. Zhang CC, Zhou CZ, Burnap RL, Peng L. Carbon/nitrogen metabolic balance: lessons from cyanobacteria. Trends in plant science. 2018; 23(12):1116-1130.
19. Enwonwu CO, Xu XX, Turner E. Nitrogen metabolism in sickle cell anemia: free amino acids in plasma and urine. The American journal of the medical sciences. 1990; 300(6):366-371.
20. Borel MJ, Buchowski MS, Turner EA, Peeler BB, Goldstein RE, Flakoll PJ. Alterations in basal nutrient metabolism increase resting energy expenditure in sickle cell disease. American Journal of Physiology-Endocrinology and Metabolism. 1998; 274(2):E357-364.
21. Jackson AA. The use of stable isotopes to study nitrogen metabolism in homozygous sickle cell disease. InGenetic factors in nutrition. 1984: 297-315. Academic Press, New York.
22. Schnog JJ, Jager EH, van der Dijs FP, Duits AJ, Moshage H, Muskiet FD, Muskiet FA. Evidence for a metabolic shift of arginine metabolism in sickle cell disease. Annals of Hematology. 2004; 83:371-375.
23. Darghouth D, Koehl B, Madalinski G, Heilier JF, Bovee P, Xu Y, Olivier MF, Bartolucci P, Benkerrou M, Pissard S, Colin Y. Pathophysiology of sickle cell disease is mirrored by the red blood cell metabolome. Blood, The Journal of the American Society of Hematology. 2011; 117(6):e57-66.
24. Morris CR, Kato GJ, Poljakovic M, Wang X, Blackwelder WC, Sachdev V, Hazen SL, Vichinsky EP, Morris SM, Gladwin MT. Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease. Jama. 2005; 294(1):81-90.
25. Zhou Y, Yu X, Nicely A, Cunningham G, Challa C, McKinley K, Nickel R, Campbell A, Darbari D, Summar M, Majumdar S. Amino acid signature during sickle cell pain crisis shows significant alterations related to nitric oxide and energy metabolism. Molecular genetics and metabolism. 2022; 137(1-2):146-152.
26. D'Alessandro A, Nouraie SM, Zhang Y, Cendali F, Gamboni F, Reisz JA, Zhang X, Bartsch KW, Galbraith MD, Espinosa JM, Gordeuk VR. Metabolic signatures of cardiorenal dysfunction in plasma from sickle cell patients as a function of therapeutic transfusion and hydroxyurea treatment. Haematologica. 2023; 108(12):3418.
27. Obeagu EI, Obeagu GU. Management of diabetes mellitus patients with sickle cell anemia: challenges and therapeutic approaches. Medicine. 2024; 103(17):e37941.
28. Obeagu EI, Chukwu PH. Inclusive Healthcare Approaches for HIV-Positive Sickle Cell Disease Patients: A Review. Current Research in Biological Sciences. 2025;1(1):01-8.
29. Obeagu EI, Obeagu GU. Managing gastrointestinal challenges: diarrhea in sickle cell anemia. Medicine. 2024; 103(18):e38075.
30. Obeagu EI, Obeagu GU. Living with sickle cell in Uganda: A comprehensive perspective on challenges, coping strategies, and health interventions. Medicine. 2024 Dec 20;103(51):e41062.
31. Obeagu EI, Adias TC, Obeagu GU. Advancing life: innovative approaches to enhance survival in sickle cell anemia

patients. Annals of Medicine and Surgery. 2024; 86(10):6021-6036.
32. Bell V, Varzakas T, Psaltopoulou T, Fernandes T. Sickle cell disease update: new treatments and challenging nutritional interventions. Nutrients. 2024; 16(2):258.
33. Khan SA, Damanhouri G, Ali A, Khan SA, Khan A, Bakillah A, Marouf S, Al Harbi G, Halawani SH, Makki A. Precipitating factors and targeted therapies in combating the perils of sickle cell disease---A special nutritional consideration. Nutrition & metabolism. 2016; 13:1-2.
34. Patel S, Patel R, Mukkala SR, Akabari A. Emerging therapies and management approaches in sickle cell disease (SCD): A critical review. Journal of Phytonanotechnology and Pharmaceutical Sciences. 2023; 3(3):1-1.
35. Obeagu EI, Adias TC, Obeagu GU. Advancing life: innovative approaches to enhance survival in sickle cell anemia patients. Annals of Medicine and Surgery. 2024; 86(10):6021-6036.
36. Boma PM, Kaponda AA, Panda J, Bonnechère B. Enhancing the management of pediatric sickle cell disease by integrating functional evaluation to mitigate the burden of vaso-occlusive crises. Journal of Vascular Diseases. 2024; 3(1):77-87.
37. Obeagu EI, Chukwu PH. Inclusive Healthcare Approaches for HIV-Positive Sickle Cell Disease Patients: A Review. Current Research in Biological Sciences. 2025;1(1):01-8.